Defence Therapeutics’ ARM-X cancer vaccine effective in ovarian cancer models
June 26, 2024
Defence Therapeutics Inc. has demonstrated that its second-generation ARM-X anticancer vaccine is therapeutically effective against pre-established ovarian cancer (ID8 model) when combined with an anti-PD-1 immune checkpoint inhibitor.